CSL Aandeel

CSL Investeringen

Delisted·19 jun 2026

De Totale Investeringen van CSL (CSL.AX) per 14 aug 2026 bedraagt 203,00 Miljoen USD. In het voorgaande jaar bedroeg Totale Investeringen 163,00 Miljoen USD — een verandering van 24,54% (hoger).

Investeringen

203,00 MiljoenUSD

YoY

24,54%

Laatst bijgewerkt:

Totale Investeringen van CSL is 2026 203,00 Miljoen USD. Totale Investeringen van CSL was 2025 163,00 Miljoen USD. Het is daarmee 24,54% hoger lager dan het jaar ervoor.
Access this data via the Eulerpool API

CSL Aandelenanalyse

Wat doet CSL? CSL Ltd is a global leading company in the field of biological medicine, manufacturing a wide range of products used in the therapy of diseases. The company is based in Melbourne, Australia, and is one of the largest biotech companies in the country. CSL was founded in 1916 by Australian researcher Frank Macfarlane Burnet. Originally named Commonwealth Serum Laboratories, the company focused on the research and production of vaccines. CSL was then privatized in 1994 and changed its name to CSL Ltd. CSL's business model is based on the production of protein products and plasma derivatives used in immunotherapy, hematology, and transplantation medicine. The company specializes in the production and marketing of products in three main areas: plasma products, vaccines, and animal health. CSL's plasma division includes a variety of products, including intravenous immunoglobulins (IVIG), platelets, and alpha-1 antitrypsin. The company operates a number of plasma centers in the US and Europe to collect raw materials for these products. In the vaccine sector, CSL is primarily involved in the manufacture of influenza vaccines and also offers a range of other vaccines, including vaccines against snake bites and encephalitis. In the field of animal health, CSL produces animal vaccines to prevent viral infections in livestock such as pigs, poultry, and cattle. CSL is committed to research and development to develop new products and improve existing ones. The company has a long history in the research and development of vaccines and immunotherapies and has established a strong presence in this field. The company employs over 27,000 people in 35 countries worldwide and operates production facilities in Australia, the US, Europe, and Asia. CSL's headquarters are located in Parkville, a suburb of Melbourne, Australia. CSL has an impressive track record in terms of growth and profitability and is a stable market leader in its field. The company has achieved solid growth rates in recent years and generated a revenue of $8.5 billion in 2019. CSL is a key player in the global healthcare industry and has established a reputation as a reliable supplier of medical products and services. The company is committed to developing innovative solutions to advance medical progress and make a positive contribution to human health. CSL is een van de meest populaire bedrijven op Eulerpool.

Veelgestelde vragen over het aandeel CSL

Totale Investeringen van CSL bedraagt 203,00 Miljoen USD in 2026.

Totale Investeringen van CSL is veranderd van 163,00 Miljoen USD naar 203,00 Miljoen USD, wat een verandering van 24,54% vertegenwoordigt. De waarde is hoger dan het vorige jaar.

Op Eulerpool vindt u de volledige historische ontwikkeling van Totale Investeringen CSL sinds 2006 – met jaarlijkse waarden, grafieken en gedetailleerde analyse.

Totale beleggingen omvatten zowel kortlopende als langlopende effecten die door een bedrijf worden aangehouden.

USD van Totale Investeringen is een belangrijke factor voor beleggers. Veranderingen in deze maatstaf kunnen sterke signalen geven voor toekomstige koersontwikkelingen.

Access this data via the Eulerpool API

Balans — CSL

Alle kengetallen — CSL